Clinical trials: High-Risk Cancer
Metastatic and/or High Risk Solid Tumor of Children
Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids
The search for genetic alterations in primary tumor by NGS techniques followed by the detection of these alterations in circulating tumor DNA and/or CTC/DTC present in peripheral samples (blood, cerebrospinal fluid, bone marrow…
- Trial name
- NGSKids (NCT02546453)
- Testing
- Tumoral specific genetic alterations
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Curie
High-grade Serous Ovarian Cancer (HGSOC)
Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer
High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian carcinoma. Platinum-based drugs are the first-line chemotherapeutic agents for HGSOC, but platinum resistance and prognosis are difficult to…
- Trial name
- PPRPHGSOC (NCT06787170)
- Testing
- MRI habitat imaging
- Where
- China
- Volunteers
- 1,129 people
- Sponsor
- The First People's Hospital of Yunnan
Lymphoma
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00070187
- Testing
- aldesleukin, filgrastim, recombinant interferon gamma
- Where
- 63 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group
Acute Promyelocytic Leukemia
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options…
- Trial name
- NCT02938858
- Where
- 27 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Basal Cell Carcinoma, Lentigo Maligna
Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
Reflectance confocal microscopy (RCM) is the reference in vivo imaging technique for identifying malignant melanocytic tumors prior to surgical excision.
- Conditions
- Basal Cell Carcinoma, Lentigo Maligna, Melanoma, Nevus
- Trial name
- Micro3 (NCT06046144)
- Testing
- Fluorescence-Advanced videodermatoscopy, Reflectance confocal microscopy, Super-high magnification dermoscopy
- Where
- France
- Volunteers
- 161 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Breast Cancer
Study of Etoposide in Breast Cancer Patients
This study will examine how the body handles etoposide, a drug used to treat breast cancer. The knowledge gained may lead to more effective use of the drug with fewer side effects in the future.
- Trial name
- NCT00026949
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Glioma
Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma
RATIONALE: Current therapies for children with recurrent/progressive high grade gliomas provide very limited benefit to the patient.
- Trial name
- NCT00003535
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
- Trial name
- NCT00069940
- Testing
- sargramostim, telomerase: 540-548 peptide vaccine
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell
ChiCGB vs BEAM in High-risk or R/R Lymphomas
High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) plays a vital role in treating high-risked or relapsed/refractory lymphoma.
- Trial name
- NCT05466318
- Testing
- Chidamide, Cladribine, Gemcitabine
- Where
- 11 sites in China
- Volunteers
- 306 people
- Sponsor
- Sichuan University
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult, Lymphoblastic Leukemia in Children
- Trial name
- ALaCART (NCT05038696)
- Testing
- CAR T-cell therapy
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National University Hospital, Singapore
Gastrointestinal Stromal Tumors, Minimal Residual Disease
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
So far, MRD assessment by liquid biopsy (ctDNA) has not been used to predict postoperative treatment efficacy and recurrence risk of GIST patients because of special disease characteristics and technological limitations.
- Trial name
- NCT05408897
- Testing
- liquid biopsy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma
- Trial name
- NCT03136146
- Testing
- Bortezomib, Clofarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma, Soft Tissue Sarcoma
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT04906876
- Testing
- Gemcitabine, Docetaxel, 9-ING-41
- Where
- 2 sites in United States
- Sponsor
- Brown University
Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing melphalan directly to the tumor may kill more tumor cells and cause less damage to healthy tissues.
- Conditions
- Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT00019968
- Testing
- melphalan, tumor necrosis factor
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Neuroblastoma, Sarcoma
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells.
- Trial name
- NCT00003023
- Testing
- BCG vaccine, monoclonal antibody A1G4 anti-idiotype vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Secondary Caries, Fracture Tooth
Clinical Assessment of Injectable Flowable Composite with Giomer Technology Vs High Viscosity Glass Ionomer Restorations in ART for Cancer Patients
Aim of the Study: This study will compare between injectable flowable composite (Beautifil flow plus x) and high viscosity glass ionomer (Equia Fil) by ART caries preventive protocol in high caries risk patients receiving…
- Conditions
- Secondary Caries, Fracture Tooth, Discoloration, Tooth
- Trial name
- NCT05465369
- Testing
- giomer, high viscosity glass ionomer
- Where
- Egypt
- Volunteers
- 190 people
- Sponsor
- Cairo University
Medulloblastoma
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
- Trial name
- NCT04696029
- Testing
- Difluoromethylornithine
- Where
- 26 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Giselle Sholler
Multiple Myeloma, Lymphocytic Leukemia, Chronic
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
- Conditions
- Multiple Myeloma, Lymphocytic Leukemia, Chronic, Lymphoma, Low-Grade
- Trial name
- NCT00143845
- Testing
- Reduced intensity conditioning, Rapid immunosuppressive taper, Prophylactic donor leukocyte infusions
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.